newsfilter
← Latest News
Business Wire·

Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

PALIZADE Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis on track to initiate in first half of 2023 KZR-261 dose escalation study continues to progress; the dose expansion study expected to